Sandbox 20001: Difference between revisions

From Proteopedia
Jump to navigationJump to search
Joel L. Sussman (talk | contribs)
No edit summary
Joel L. Sussman (talk | contribs)
No edit summary
Line 17: Line 17:
== Recent published papers ==
== Recent published papers ==


* A recent study by Gautret ''et al''. (2020) showed, despite its small sample size (20 patients treated), that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.<ref>Gautret, et al. "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial: Intl J Antimcrob Agents" (in press) 2020     [http://dx.doi.org/10.1016/j.ijantimicag.2020.105949]</ref>
* A recent study by Gautret ''et al''. (2020) showed, despite its small sample size (20 patients treated), that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.<ref>Gautret, et al. "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial: Intl J Antimcrob Agents" (in press) 2020 [http://dx.doi.org/10.1016/j.ijantimicag.2020.105949]</ref>
 
* Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of COVID-19 in China; some promising results have been achieved thus far and are summarizes agents with potential efficacy against SARS-CoV-2. <ref>PMID:32147628</ref>





Revision as of 10:55, 21 March 2020

Coronavirus Disease 2019 (COVID-19)

Drag the structure with the mouse to rotate

References